Bill Text: IA SF2198 | 2017-2018 | 87th General Assembly | Introduced
Bill Title: A bill for an act relating to the Iowa prescription monitoring program, including by establishing an advisory committee, authorizing a registration surcharge, expanding information collection and reporting requirements, and making penalties applicable. (Formerly SSB 3071.)
Sponsorship: Committee Bill
Status: (Introduced - Dead) 2018-03-15 - Referred to Human Resources. S.J. 692. [SF2198 Detail]
Download: Iowa-2017-SF2198-Introduced.html
Senate File 2198 - Introduced SENATE FILE BY COMMITTEE ON HUMAN RESOURCES (SUCCESSOR TO SSB 3071) A BILL FOR 1 An Act relating to the Iowa prescription monitoring program, 2 including by establishing an advisory committee, authorizing 3 a registration surcharge, expanding information collection 4 and reporting requirements, and making penalties applicable. 5 BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA: TLSB 5275SV (1) 87 ss/rh PAG LIN 1 1 Section 1. Section 124.550, Code 2018, is amended by adding 1 2 the following new subsection: 1 3 NEW SUBSECTION. 3. "Proactive notification" means 1 4 a notification by the board, generated based on factors 1 5 determined by the board and issued to a specific prescribing 1 6 practitioner or pharmacist, indicating that a patient may 1 7 be practitioner shopping or pharmacy shopping or at risk of 1 8 abusing or misusing a controlled substance. 1 9 Sec. 2. Section 124.551, subsection 1, Code 2018, is amended 1 10 to read as follows: 1 11 1. Contingent upon the receipt of funds pursuant to 1 12 section 124.557 sufficient to carry out the purposes of 1 13 this subchapter, the board, in conjunction with the advisory 1 14councilcommittee created in section 124.555, shall establish 1 15 and maintain an information program for drug prescribing and 1 16 dispensing. 1 17 Sec. 3. Section 124.552, Code 2018, is amended to read as 1 18 follows: 1 19 124.552 Information reporting. 1 20 1.EachUnless otherwise prohibited by federal or state law, 1 21 each licensed pharmacy that dispenses controlled substances 1 22 identified pursuant to section 124.554, subsection 1, paragraph 1 23 "g", to patients in the state,andeach licensed pharmacy 1 24 located in the state that dispenses such controlled substances 1 25 identified pursuant to section 124.554, subsection 1, 1 26 paragraph "g", to patients inside or outside the state, unless 1 27 specifically excepted in this section or by rule, and each 1 28 prescribing practitioner furnishing, dispensing, or supplying 1 29 controlled substances to the prescribing practitioner's 1 30 patient, shall submit the following prescription information 1 31 to the program: 1 32 a. Pharmacy identification. 1 33 b. Patient identification. 1 34 c. Prescribing practitioner identification. 1 35 d. The date the prescription was issued by the prescribing 2 1 practitioner. 2 2 e. The date the prescription was dispensed. 2 3 f. An indication of whether the prescription dispensed is 2 4 new or a refill. 2 5 g. Identification of the drug dispensed. 2 6 h. Quantity of the drug dispensed. 2 7 i. The number of days' supply of the drug dispensed. 2 8 j. Serial or prescription number assigned by the pharmacy. 2 9 k. Type of payment for the prescription. 2 10 l. Other information identified by the boardand advisory 2 11 councilby rule. 2 12 2. Information shall be submitted electronically in a 2 13 secure format specified by the board unless the board has 2 14 granted a waiver and approved an alternate secure format. 2 15 3. Information shall be timely transmitted as designated by 2 16 the boardand advisory councilby rule, unless the board grants 2 17 an extension. The board may grant an extension if either of 2 18 the following occurs: 2 19 a. The pharmacy or prescribing practitioner suffers 2 20 a mechanical or electronic failure, or cannot meet the 2 21 deadline established by the board for other reasons beyond the 2 22 pharmacy's or practitioner's control. 2 23 b. The board is unable to receive electronic submissions. 2 24 4. This section shall not apply toa prescribing 2 25 practitioner furnishing, dispensing, supplying, or 2 26 administering drugs to the prescribing practitioner's patient, 2 27 or todispensing by a licensed pharmacy for the purposes of 2 28 inpatient hospital care, inpatient hospice care, or long=term 2 29 residential facility patient care. 2 30 Sec. 4. Section 124.553, subsection 1, paragraph b, Code 2 31 2018, is amended to read as follows: 2 32 b. An individual who requests the individual's own program 2 33 information in accordance with the procedure established in 2 34 rules of the boardand advisory counciladopted under section 2 35 124.554. 3 1 Sec. 5. Section 124.553, subsection 1, Code 2018, is amended 3 2 by adding the following new paragraph: 3 3 NEW PARAGRAPH. g. A prescribing practitioner or pharmacist 3 4 through the use of a targeted distribution of proactive 3 5 notifications. 3 6 Sec. 6. Section 124.553, subsections 2, 3, and 7, Code 2018, 3 7 are amended to read as follows: 3 8 2. The board shall maintain a record of each person that 3 9 requests information from the program and of all proactive 3 10 notifications distributed to prescribing practitioners and 3 11 dispensing pharmacists as provided in subsection 1, paragraph 3 12 "g". Pursuant to rules adopted by the boardand advisory 3 13 councilunder section 124.554, the board may use the records 3 14 to document and report statistical information, and may 3 15 provide program information for statistical, public research, 3 16 public policy, or educational purposes, after removing 3 17 personal identifying information of a patient, prescribing 3 18 practitioner, dispenser, or other person who is identified in 3 19 the information. 3 20 3. Information contained in the program and any information 3 21 obtained from it, and information contained in the records 3 22 of requests for information from the program and information 3 23 distributed to prescribing practitioners and dispensing 3 24 pharmacists as provided in subsection 1, paragraph "g", 3 25 is privileged and strictly confidential information. Such 3 26 information is a confidential public record pursuant to section 3 27 22.7, and is not subject to discovery, subpoena, or other 3 28 means of legal compulsion for release except as provided in 3 29 this subchapter. Information from the program shall not be 3 30 released, shared with an agency or institution, or made public 3 31 except as provided in this subchapter. 3 32 7.TheExcept as allowed in section 124.557, the 3 33 board shall not charge a fee to a pharmacy, pharmacist, or 3 34 prescribing practitioner for the establishment, maintenance, 3 35 or administration of the program, including costs for forms 4 1 required to submit information to or access information from 4 2 the program, except that the. The board may charge a fee 4 3 to an individual who requests the individual's own program 4 4 information. A fee charged to an individual pursuant to this 4 5 subsection shall not exceed the actual cost of providing the 4 6 requested information and shall be considered a repayment 4 7 receipt as defined in section 8.2. 4 8 Sec. 7. Section 124.554, Code 2018, is amended to read as 4 9 follows: 4 10 124.554 Rules and reporting. 4 11 1. The boardand advisory council, in consultation with the 4 12 advisory committee, shalljointlyadopt rules in accordance 4 13 with chapter 17A to carry out the purposes of, and to enforce 4 14 the provisions of, this subchapter. The rules shall include 4 15 but not be limited to the development of procedures relating 4 16 to: 4 17 a. Identifying each patient about whom information is 4 18 entered into the program. 4 19 b. An electronic format for the submission of information 4 20 from pharmacies and prescribing practitioners. 4 21 c. A waiver to submit information in another format for 4 22 a pharmacy or prescribing practitioner unable to submit 4 23 information electronically. 4 24 d. An application by a pharmacy or prescribing practitioner 4 25 for an extension of time for transmitting information to the 4 26 program. 4 27 e. The submission by an authorized requestor of a request 4 28 for information and a procedure for the verification of the 4 29 identity of the requestor. 4 30 f. Use by the board or advisorycouncilcommittee of the 4 31 program request records required by section 124.553, subsection 4 32 2, to document and report statistical information. 4 33 g. Including all schedule II, schedule III, schedule IV, 4 34controlled substancesandthose substances in schedules III 4 35 and IV that the advisory council and board determine can be 5 1 addictive or fatal if not taken under the proper care and 5 2 direction of a prescribing practitionerschedule V controlled 5 3 substances except when dispensed by a pharmacist without a 5 4 prescription. 5 5 h. Access by a pharmacist or prescribing practitioner to 5 6 information in the programpursuant to a written agreement with 5 7 the board and advisory council. 5 8 i. The correction or deletion of erroneous information in 5 9 the program. 5 10 j. The establishment of thresholds or other criteria or 5 11 measures to be used in identifying an at=risk patient as 5 12 provided in section 124.553, subsection 1, paragraph "g", and 5 13 the targeted distribution of proactive notifications suggesting 5 14 review of the patient's prescription history. 5 15 k. User registration processes and requirements. 5 16 2. Beginning January1, 200715, 2019, and annually by 5 17 January115 thereafter, the board and advisorycouncil 5 18committee shall present to the general assembly and the 5 19 governor a report prepared consistent with section 124.555, 5 20 subsection 3, paragraph "d", which shall include but not be 5 21 limited to the following: 5 22 a. The cost to the state of implementing and maintaining the 5 23 program. 5 24 b. Information from pharmacies, prescribing practitioners, 5 25 the board, the advisorycouncilcommittee, and others regarding 5 26 the benefits or detriments of the program. 5 27 c. Information from pharmacies, prescribing practitioners, 5 28 the board, the advisorycouncilcommittee, and others regarding 5 29 the board's effectiveness in providing information from the 5 30 program. 5 31 Sec. 8. Section 124.555, Code 2018, is amended to read as 5 32 follows: 5 33 124.555 Advisorycouncilcommittee established. 5 34 An advisorycouncilcommittee shall be established to 5 35 provide oversight to the board and the program and to comanage 6 1 program activities. The boardand, in consultation with 6 2 the advisorycouncilcommittee, shalljointlyadopt rules 6 3 specifying the duties and activities of the advisorycouncil 6 4committee and related matters. 6 5 1. Thecouncilcommittee shall consist ofeighta minimum 6 6 of four members appointed by thegovernorboard. The members 6 7 shall include but not be limited to at least one member from 6 8 each of the following categories:threelicensed pharmacists, 6 9fourphysicians licensed under chapter 148,and onelicensed 6 10 prescribingpractitionerpractitioners whoisare nota 6 11 physicianphysicians, and public members who are not health 6 12 care professionals. Thegovernor shallboard may solicit 6 13 recommendations forcouncilcommittee members from Iowa health 6 14 professional licensing boards, associations,andsocieties, 6 15 and other interested groups. The license of each health care 6 16 professional member appointed to and serving on the advisory 6 17councilcommittee shall be current and in good standing with 6 18 the professional's licensing board. 6 19 2. Thecouncilcommittee shall advance the goals of the 6 20 program, which include identification of misuse and diversion 6 21 of controlled substances identified pursuant to section 6 22 124.554, subsection 1, paragraph "g", reduction of overdoses 6 23 and deaths as a result of prescription controlled substance 6 24 use and abuse, and enhancement of the quality of health care 6 25 delivery in this state. 6 26 3. Duties of thecouncilcommittee shall include but not be 6 27 limited to the following: 6 28 a. Ensuring the confidentiality of the patient, prescribing 6 29 practitioner, and dispensing pharmacist and pharmacy. 6 30 b. Respecting and preserving the integrity of the patient's 6 31 treatment relationship with the patient's health care 6 32 providers. 6 33 c. Encouraging and facilitating cooperative efforts 6 34 among health care practitioners and other interested and 6 35 knowledgeable persons in developing best practices for 7 1 prescribing and dispensing controlled substances and in 7 2 educating health care practitioners and patients regarding 7 3 controlled substance use and abuse. 7 4 d. Making recommendations regarding the continued benefits 7 5 of maintaining the program in relationship to cost and other 7 6 burdens to the patient, prescribing practitioner, pharmacist, 7 7 and the board. Thecouncil'scommittee's recommendations shall 7 8 be included in reports required by section 124.554, subsection 7 9 2. 7 10e. One physician and one pharmacist member of the council 7 11 shall include in their duties the responsibility for monitoring 7 12 and ensuring that patient confidentiality, best interests, and 7 13 civil liberties are at all times protected and preserved during 7 14 the existence of the program.7 15 4. Members of the advisorycouncilcommittee shall 7 16 be eligible to request and receive actual expenses for 7 17 their duties as members of the advisorycouncilcommittee, 7 18 subject to reimbursement limits imposed by the department of 7 19 administrative services, and shall also be eligible to receive 7 20 a per diem compensation as provided in section 7E.6, subsection 7 21 1. 7 22 Sec. 9. Section 124.556, Code 2018, is amended to read as 7 23 follows: 7 24 124.556 Education and treatment. 7 25 The program for drug prescribing and dispensing shall 7 26 include education initiatives and outreach to consumers, 7 27 prescribing practitioners, and pharmacists, and shall also 7 28 include assistance for identifying substance abuse treatment 7 29 programs and providers. The board and advisorycouncil 7 30committee shall adopt rules, as provided under section 124.554, 7 31 to implement this section. 7 32 Sec. 10. Section 124.557, Code 2018, is amended to read as 7 33 follows: 7 34 124.557 Drug information program fund. 7 35 The drug information program fund is established to be used 8 1 by the board to fund or assist in funding the program. The 8 2 board may make deposits into the fund from any source, public 8 3 or private, including grants or contributions of money or other 8 4 items of value, which it determines necessary to carry out the 8 5 purposes of this subchapter. The board may add a surcharge 8 6 of not more than twenty=five percent to the applicable fee 8 7 for a registration issued pursuant to section 124.302 and the 8 8 surcharge shall be deposited into the fund. Moneys received 8 9 by the board to establish and maintain the program must 8 10 be used for the expenses of administering this subchapter. 8 11 Notwithstanding section 8.33, amounts contained in the fund 8 12 that remain unencumbered or unobligated at the close of the 8 13 fiscal year shall not revert but shall remain available for 8 14 expenditure for the purposes designated in future years. 8 15 Sec. 11. Section 124.558, subsection 1, Code 2018, is 8 16 amended to read as follows: 8 17 1. Failure to comply with requirements. A pharmacist, 8 18 pharmacy, prescribing practitioner, or agent of a pharmacist 8 19 or prescribing practitioner who knowingly fails to comply 8 20 with the confidentiality requirements of this subchapter 8 21 or who delegates program information access to another 8 22 individual except as provided in section 124.553, is subject to 8 23 disciplinary action by the appropriate professional licensing 8 24 board. A pharmacist,orpharmacy, or prescribing practitioner 8 25 that knowingly fails to comply with other requirements of this 8 26 subchapter is subject to disciplinary action by the board. 8 27 Each licensing board may adopt rules in accordance with chapter 8 28 17A to implement the provisions of this section. 8 29 Sec. 12. TRANSITION == APPOINTMENT AND TERMS OF ADVISORY 8 30 COMMITTEE MEMBERS. This Act's amendments changing the name of 8 31 the "advisory council" to the "advisory committee" shall not 8 32 affect the appointment of a member who served on the advisory 8 33 council immediately prior to the effective date of this Act. 8 34 That member shall continue to serve on the advisory committee 8 35 at the pleasure of the governor. 9 1 Sec. 13. TRANSITION == ADMINISTRATIVE RULES AND OTHER 9 2 ACTIONS AND DOCUMENTS. Any rule, form, order, or directive 9 3 promulgated by the advisory council created in section 124.550, 9 4 in force and effect immediately prior to the effective date of 9 5 this Act, shall continue in full force and effect until the 9 6 earlier of the following: 9 7 1. It is amended, rescinded, or supplemented by the 9 8 affirmative actions of the board of pharmacy. 9 9 2. It expires by its own terms. 9 10 EXPLANATION 9 11 The inclusion of this explanation does not constitute agreement with 9 12 the explanation's substance by the members of the general assembly. 9 13 This bill alters the Iowa prescription monitoring program 9 14 (PMP) by establishing an advisory committee, authorizing a 9 15 registration surcharge, expanding information collection and 9 16 reporting requirements, and making penalties applicable to 9 17 dispensing practitioners. 9 18 The bill adds dispensing prescribers to the list of persons 9 19 required to report to the PMP the dispensation of reportable 9 20 controlled substances to patients in Iowa, subject to the 9 21 same exceptions provided to pharmacies, unless otherwise 9 22 prohibited by state or federal law. The bill also eliminates 9 23 the PMP advisory council and creates an advisory committee to 9 24 assume the duties of the advisory council, with members to be 9 25 appointed from among health care professionals and the general 9 26 public by the board in numbers to be determined by the board, 9 27 provided the committee consists of at least four members. 9 28 The bill provides that members of the advisory council shall 9 29 continue to serve on the advisory committee and that any 9 30 rule, form, order, or directive promulgated by the advisory 9 31 council shall continue to be in force and effect until they are 9 32 amended, rescinded, or supplemented by the board of pharmacy 9 33 or expire by their own terms. 9 34 The bill also allows the board, in consultation with 9 35 the PMP advisory committee, to establish criteria for the 10 1 identification of patients who are potentially misusing or 10 2 abusing prescription controlled substances and authorizes the 10 3 board to proactively notify the pharmacists and prescribing 10 4 practitioner involved in the patient's care of its concerns. 10 5 The bill authorizes the collection of dispensing records for 10 6 all schedule II, III, IV, and V controlled substances except 10 7 when the schedule V controlled substance is dispensed by a 10 8 pharmacist without a prescription. The bill also authorizes, 10 9 but does not require, the board to impose a surcharge to 10 10 be deposited into the drug information program fund on 10 11 controlled substances Act registrations, which any person who 10 12 manufactures, distributes, or dispenses a controlled substance 10 13 must obtain and maintain, to be used for the expenses of 10 14 administering the PMP. 10 15 The bill adds to the goals of the program the reduction of 10 16 overdoses and deaths as a result of prescription controlled 10 17 substance use and abuse. The bill also changes the due 10 18 date for annual reports to the governor and the legislature 10 19 regarding the program from January 1 to January 15. 10 20 The bill makes prescribing practitioners subject to 10 21 disciplinary action by the board under Code section 124.558 for 10 22 failure to comply with the reporting requirement. LSB 5275SV (1) 87 ss/rh
